Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

689 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Breast cancer.
Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, Ruddy K, Tsang J, Cardoso F. Harbeck N, et al. Nat Rev Dis Primers. 2019 Sep 23;5(1):66. doi: 10.1038/s41572-019-0111-2. Nat Rev Dis Primers. 2019. PMID: 31548545 Review.
Antibody therapy for breast cancer.
Willems A, Gauger K, Henrichs C, Harbeck N. Willems A, et al. Among authors: harbeck n. Anticancer Res. 2005 May-Jun;25(3A):1483-9. Anticancer Res. 2005. PMID: 16033049 Free article. Review.
Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients.
Harbeck N, Nimmrich I, Hartmann A, Ross JS, Cufer T, Grützmann R, Kristiansen G, Paradiso A, Hartmann O, Margossian A, Martens J, Schwope I, Lukas A, Müller V, Milde-Langosch K, Nährig J, Foekens J, Maier S, Schmitt M, Lesche R. Harbeck N, et al. J Clin Oncol. 2008 Nov 1;26(31):5036-42. doi: 10.1200/JCO.2007.14.1697. Epub 2008 Aug 18. J Clin Oncol. 2008. PMID: 18711169
Recommendations for collection and handling of specimens from group breast cancer clinical trials.
Leyland-Jones BR, Ambrosone CB, Bartlett J, Ellis MJ, Enos RA, Raji A, Pins MR, Zujewski JA, Hewitt SM, Forbes JF, Abramovitz M, Braga S, Cardoso F, Harbeck N, Denkert C, Jewell SD; Breast International Group; Cooperative Groups of the Breast Cancer Intergroup of North America (TBCI); American College of Surgeons Oncology Group; Cancer and Leukemia Group B; Eastern Cooperative Oncology Group; North Central Cancer Treatment Group; National Cancer Institute of Canada Clinical Trials Group; Southwest Oncology Group; National Surgical Adjuvant Breast and Bowel Project; Radiation Oncology Group; Gynecologic Oncology Group; Children's Oncology Group. Leyland-Jones BR, et al. Among authors: harbeck n. J Clin Oncol. 2008 Dec 1;26(34):5638-44. doi: 10.1200/JCO.2007.15.1712. Epub 2008 Oct 27. J Clin Oncol. 2008. PMID: 18955459 Free PMC article.
Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker.
Sadr-Nabavi A, Ramser J, Volkmann J, Naehrig J, Wiesmann F, Betz B, Hellebrand H, Engert S, Seitz S, Kreutzfeld R, Sasaki T, Arnold N, Schmutzler R, Kiechle M, Niederacher D, Harbeck N, Dahl E, Meindl A. Sadr-Nabavi A, et al. Among authors: harbeck n. Int J Cancer. 2009 Apr 1;124(7):1727-35. doi: 10.1002/ijc.24108. Int J Cancer. 2009. PMID: 19115204 Free article.
Angiogenesis inhibitors in the management of breast cancer.
Bossung V, Harbeck N. Bossung V, et al. Among authors: harbeck n. Curr Opin Obstet Gynecol. 2010 Feb;22(1):79-86. doi: 10.1097/GCO.0b013e328334e462. Curr Opin Obstet Gynecol. 2010. PMID: 19952746 Review.
Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.
Miles DW, Chan A, Dirix LY, Cortés J, Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F, Harbeck N, Steger GG, Schneeweiss A, Wardley AM, Chlistalla A, Romieu G. Miles DW, et al. Among authors: harbeck n. J Clin Oncol. 2010 Jul 10;28(20):3239-47. doi: 10.1200/JCO.2008.21.6457. Epub 2010 May 24. J Clin Oncol. 2010. PMID: 20498403 Clinical Trial.
689 results